Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Waste Management, Inc. (WM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Waste Management, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Waste Management, Inc. trades at $234.4 (market cap $93.70B). The key difference: Waste Management, Inc. is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Waste Management, Inc. pays a 1.52% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WM | |
|---|---|---|
Market Cap | $39.89B | $93.70B |
Sector | Health | Industrials |
52-Week High | $491.22 | $246.51 |
52-Week Low | $278.09 | $196.77 |
Enterprise Value | $38.15B | $116.43B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
WM trades at $233.33, up 0.72% today, showing steady performance near its 52-week high. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, revenue grew to $25.20B in 2025 with a net income margin of 10.99%, though recent quarters show mixed earnings results. Analyst consensus remains positive with a $263.57 price target. The company continues its dividend payments, with the next $0.95 dividend scheduled for June 2026.
Outlook: WM's defensive business model and pricing power provide stability, but elevated valuation ratios (P/E 33.77) pose risks if growth slows. Upside potential exists if the company meets Q2 2026 earnings expectations. Key risks include debt levels and economic sensitivity. Wall Street's strong buy sentiment (57% buy ratings) supports a cautiously optimistic view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
